Shanghai Henlius Biotech Inc (2696)

Currency in HKD
74.25
+0.90(+1.23%)
Closed·

2696 Financial Summary

Key Ratios

P/E Ratio19.95
Price/Book5.43
Debt / Equity121.06%
Return on Equity31.52%
Dividend Yield0.00%
EBITDA1.16B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Analyst Ratings

4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 61.59
(-17.05% Downside)

Earnings

Latest Release
Apr 15, 2025
EPS / Forecast
0.80 / --
Revenue / Forecast
2.98B / --
EPS Revisions
Last 90 days

FAQ

What were Henlius Biotech's earnings for the latest quarter?

The Henlius Biotech EPS (TTM) is 1.51. Henlius Biotech reported sales of 2,978.34, net income of 434.17, and EPS of 0.80 for the latest quarter.

What was Henlius Biotech's net income for the latest quarter?

Henlius Biotech's net income for the latest quarter was 434.17.

How did Henlius Biotech's performance compare year-over-year in the latest quarter?

The company's revenue moved from 2,746.11 in the previous quarter to 2,978.34 in the latest quarter, and net income moved from 386.30 to 434.17 compared to the previous quarter.

What is Henlius Biotech's net profit margin on a TTM basis?

Henlius Biotech's trailing twelve months (TTM) net profit margin is 14.33%.

How does Henlius Biotech's debt to equity ratio compare to industry standards?

Henlius Biotech's total debt-to-equity ratio is 121.06%.

What is Henlius Biotech's return on investment on a TTM basis?

Henlius Biotech's trailing twelve months (TTM) return on investment (ROI) is 31.52%.

Did Henlius Biotech gain or lose cash last quarter?

In the latest quarter, Henlius Biotech's net change in cash was 257.49 million.

What were Henlius Biotech's total assets and liabilities in the latest quarter?

As of the latest quarter, Henlius Biotech reported total assets of 10,597.52 million and total liabilities of 5,032.00 million.

How has Henlius Biotech's total revenue grown this year?

Henlius Biotech's total revenue was 2,746.11 in the previous quarter and 2,978.34 in the latest quarter.

What is Henlius Biotech's gross margin on a TTM basis?

Henlius Biotech's trailing twelve months (TTM) gross margin is 73.10%.

What was Henlius Biotech's revenue per share for the latest quarter?

Henlius Biotech's revenue per share for the latest quarter was 5.23.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.